Biosimilars Documentation Form

ONTARIO PHARMACISTS ASSOCIATION
Advocating Excellence in Practice and Care

Date

Patient Information	
Last Name	**First Name**
OHN	**DOB**
Address	
Sex ☐ **M** ☐ **F** ☐ **X**	**Phone**

Primary Care Provider Information	
Name	
Fax	**Phone**
Consent obtained from: ☐ **Patient** ☐ **Patient's Agent:**	

Prescription Information by Prescriber		
Originator Biologic that the Patient Must <u>Stop</u>	**Biosimilar that has been Prescribed to <u>Start</u>**	**Indication**
☐ Humira (Adalimumab)	☐ Abrilada® ☐ Amgevita® ☐ Hadlima® ☐ Hulio® ☐ Hyrimoz® ☐ Idacio® ☐ Simlandi® ☐ Yuflyma®	☐ Ankylosing Spondylitis ☐ Crohn's Disease ☐ Hidradenitis Suppurativa ☐ Plaque Psoriasis ☐ Polyarticular Juvenile Idiopathic Arthritis ☐ Psoriatic Arthritis ☐ Rheumatoid Arthritis ☐ Ulcerative Colitis ☐ Uveitis
☐ Enbrel (Etanercept)	☐ Brenzys® ☐ Erelzi®	☐ Ankylosing Spondylitis ☐ Plaque Psoriasis ☐ Polyarticular Juvenile Idiopathic Arthritis ☐ Psoriatic Arthritis ☐ Rheumatoid Arthritis
☐ Copaxone (Glatiramer acetate)	☐ Glatect™	☐ Relapsing Remitting Multiple Sclerosis (RRMS)
☐ Remicade (Infliximab)	☐ Avsola® ☐ Inflectra® ☐ Renflexis®	☐ Ankylosing Spondylitis ☐ Crohn's Disease ☐ Plaque Psoriasis ☐ Psoriatic Arthritis ☐ Rheumatoid Arthritis ☐ Ulcerative Colitis
☐ NovoRapid (Insulin aspart)	☐ Kirsty® ☐ Trurapi®	☐ Diabetes (Type 1 and 2)
☐ Lantus (Insulin glargine)	☐ Basaglar® ☐ Semglee®	☐ Diabetes (Type 1 and 2)
☐ Humalog (Insulin lispro)	☐ Admelog®	☐ Diabetes (Type 1 and 2)
☐ Rituxan (Rituximab)	☐ Riabni® ☐ Riximyo® ☐ Ruxience™ ☐ Truxima™	☐ Rheumatoid Arthritis ☐ Granulomatosis with Polyangiitis (GPA or Wegener's Granulomatosis ☐ Microscopic Polyangiitis (MPA)

Prescription Information by Prescriber
Date Last Dispensed for the Stopped Originator Biologic Drug (if available)
Affix <u>old</u> prescription label (with the old prescription #, strength, quantity, directions for use, refills visible) (if available)
Affix <u>new</u> prescription label (with the new prescription #, strength, quantity, directions for use, refills visible)

Summary of Discussion with Patient

Check all that apply:

- ☐ Confirmed validity of prescription by prescriber
- ☐ Rationale for transition to biosimilar due to the implementation of the Biosimilar Initiative Policy in Ontario discussed with the patient
- ☐ Mentioned stopping originator biologic medication and to begin biosimilar medication with the patient
- ☐ Storage of medication and other related counselling points reviewed with the patient
- ☐ Patient informed to report any adverse events right away to pharmacist, prescriber, or seek medical help

Additional Notes:

Follow Up Plan (if applicable)			
Date Scheduled for Follow-up Consultation (YY/MM/DD)			
Method of Contact:	☐ **In Pharmacy**	☐ **Telephone:**	☐ **Other:**
Actual Date of Follow-up			
Results from Follow-up Consultation and Next Steps (including assessing adherence, control and management of condition, any adverse effects)			

Pharmacist Information	
Name	**OCP #**
Pharmacist Signature:	
Pharmacy Information (A pharmacy stamp is suitable)	

Billing Support
Patient Support Fee PINs can only be claimed for transitioning ODB recipients between March 31, 2023, and December 28, 2023, subject to certain exceptions. Note: for more information on additional exceptions to claiming a fee, please refer to the Executive Officer Notice.

Drug Product	Biosimilar Patient Support Fee PINs
Adalimumab	☐ 09858133
Etanercept	☐ 09858104
Glatiramer acetate	☐ 09858107
Infliximab	☐ 09858105
Insulin aspart	☐ 09858238
Insulin glargine	☐ 09858108
Insulin lispro	☐ 09858132
Rituximab	☐ 09858106

Disclaimer
This tool was developed by the Ontario Pharmacists Association (OPA). This resource is provided to pharmacy professionals for informational purposes only and is intended to assist pharmacy professionals during discussions with patients about switching from Biologic drugs to Biosimilar drugs but does not replace professional judgment and responsibilities. It is provided without warranty of any kind by OPA and OPA assumes no responsibility for any errors, omissions or inaccuracies therein. The decision for use and application of this document is the responsibility of the user. OPA assumes no liability for such use and application or any resulting outcomes. It is the responsibility of the pharmacy professional to use professional judgment in evaluating this material in light of any relevant clinical or situational data. It is intended to supplement materials provided by regulatory authorities, and should there be any discrepancies, municipal, provincial, and federal laws, policies and guidelines shall prevail. This information is up to date as at the date of publication. Pharmacy professionals are encouraged to confirm information with additional resources.

Updated October 19, 2023